A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes

N/ANot Yet RecruitingNCT07004153

G2e Co., Ltd152 enrolled

Overview

This study evaluates the efficacy and safety of the DIA:CONN P8, an electric smart insulin pen equipped with a Setup Wizard, CGM-based insulin injection coaching, and a bolus calculator. The device is designed to support patients with type 1 or type 2 diabetes who are on multiple daily insulin injections (MDI). The study compares the outcomes of patients using these advanced features to those using only the injection and recording functions of the device. The rationale stems from previous research showing that structured education in combination with CGM improves glycemic control in patients with diabetes. The DIA:CONN P8 aims to replicate the benefits of such structured education through app-based coaching and algorithm-driven recommendations, potentially reducing the burden of complex insulin dose calculations in routine care. Participants will undergo a run-in period using DIA:CONN P8 with injection-only functionality to assess compliance. Eligible subjects will then be randomized into either the investigational group (using all device functions) or the control group (injection and recording only). Over 12 weeks, the primary endpoint is the change in HbA1c. Secondary outcomes include CGM-based metrics such as Time in Range (TIR), Time Below Range (TBR), and insulin dosing behavior. The study is designed as a multicenter, open-label, randomized, comparative confirmatory trial conducted at six sites. A total of 152 subjects will be enrolled.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

152

Conditions

Diabetes Mellitus

Interventions

Smart Coaching Insulin PenDEVICE

Subjects randomized to the intervention group will use the DIA:CONN P8 smart insulin pen with full functionality, including Setup Wizard, CGM-based insulin injection coaching, and a bolus calculator. During the 12-week application period, including the baseline visit, participants will visit the hospital up to 5 times. At the start of the period, initial basal and bolus doses will be determined using the Setup Wizard and reviewed by investigators. Throughout the study, subjects will receive real-time insulin dose recommendations and coaching via the DIA:CONN app based on CGM data, carbohydrate input, and insulin dosing history.

Eligibility

Sex: ALLMin age: 19 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age between 19 and 75 years old. 2. Diagnosis of type 1 or type 2 diabetes for at least 1 year prior to screening 3. Continuous use of MDI therapy for at least 3 months prior to screening, defined as one of the following regimens: * Long-acting insulin plus rapid-/short-acting insulin * Mixed insulin (e.g., insulin aspart/insulin degludec) plus rapid-/short-acting insulin * Mixed insulin ≥3 times per day 4. HbA1c of 7.5% to 12.0% at screening. Exclusion Criteria: 1. Diabetes mellitus secondary to pancreatic resection. 2. Use of corticosteroids exceeding a prednisolone-equivalent dose of 5 mg/day within 3 months prior to screening (Subjects on a stable dose for ≥3 months prior to screening may be eligible). 3. eGFR \<15 mL/min at screening or those receiving dialysis 4. Pregnant or lactating women

Locations (1)

Samsung Medical Center

Seoul, Gangnam-gu, South Korea

Outcomes

Primary Outcomes

Change in HbA1c(%) at 12 weeks compared to baseline

Descriptive statistics (sample size, mean, standard deviation, median, minimum, and maximum) are provided for the change in HbA1c (%) from baseline to the 12-week time point, stratified by group.

Time frame: from baseline to the 12-week time point

Central Contacts

SOOHYUN YOON

CONTACT

+82-10-3352-4744 soohyun.yoon@g2e.co.kr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.